KRRO
Korro Bio, Inc.
Latest Form 4:Sale$4KbyFORMELA JEAN FRANCOIS (Director) · filed Aug 28, 2026
Korro Bio, Inc. (KRRO) has 34 SEC Form 4 filings (49 transaction rows) in the rolling window, disclosed by 16 distinct insiders. Most recent filing: Aug 28, 2026.
The most active filer is Director FORMELA JEAN FRANCOIS with 9 filings. Insiders have net bought $15.9M over the trailing 6 months. The largest single insider purchase in this window was $2.3M by 10% Owner BASKETT FOREST on Mar 10, 2026.
- Industry:Biotechnology
- CEO:Ram Aiyar
- Employees:49
- HQ:Cambridge, MA, US
- IPO:2019-10-03
Insider Buying
$20.8M
reported purchases (SEC code P)
Insider Selling
$4.9M
reported sales (SEC code S)
Unique Insiders
16
in the rolling window
Market Cap
$190.1M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 300 | $4K | Aug 28 | SEC ↗ | |
| Director | Sale | 28,468 | $399K | Aug 21 | SEC ↗ | |
| 10% Owner | Purchase | 5,222 | $60K | Aug 13 | SEC ↗ | |
| 10% Owner | Purchase | 1,462 | $19K | Aug 13 | SEC ↗ | |
| Director | Sale | 2,143 | $30K | Aug 13 | SEC ↗ | |
| President and CEO | Sale | 5,802 | $63K | Aug 5 | SEC ↗ | |
| Director | Sale | 100,700 | $1.4M | Jul 7 | SEC ↗ | |
| Director | Sale | 9,323 | $130K | Jul 7 | SEC ↗ | |
| Director | Sale | 3,962 | $55K | Jun 25 | SEC ↗ | |
| Director | Sale | 119,005 | $1.7M | Jun 25 | SEC ↗ | |
| Director | Sale | 48,438 | $707K | Jun 25 | SEC ↗ | |
Chappell ToddFirst filing | Chief Operating Officer | Sale | 3,168 | $34K | Jun 17 | SEC ↗ |
Dolan OliverFirst filing | Senior Vice President, Finance | Sale | 3,383 | $37K | Jun 17 | SEC ↗ |
Vincent Loic AFirst filing | Chief Scientific Officer | Sale | 3,418 | $37K | Jun 17 | SEC ↗ |
Cerio JeffreyFirst filing | General Counsel | Sale | 6,609 | $72K | Jun 17 | SEC ↗ |
Aiyar RamFirst filing | President and CEO | Sale | 15,152 | $197K | Jun 2 | SEC ↗ |
FORMELA JEAN FRANCOISFirst filing | Director | Sale | 2,860 | $40K | Jun 1 | SEC ↗ |
Lynx1 Capital Management LPFirst in 3 months | 10% Owner | Purchase | 520 | $6K | Apr 2 | SEC ↗ |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ | |
| 10% Owner | Purchase | 207,100 | $2.3M | Mar 12 | SEC ↗ |
Related companies
Korro Bio, Inc. is in the Healthcare sector.